Skip to content

Study · Randomized controlled trial · n = 27 · 2024

3 results

FDG-PET/CT-based respiration-gated lung segmentation and quantification of lung inflammation in COPD patients.

Dogan ADA, Christensen TQ, Jensen TT, Juhl CB, Hilberg O, Bladbjerg EM, Hess S

BMC research notes20 Jun 2024Cited by 1 (Europe PMC)

PMID38902794 (opens in a new tab)PMCIDPMC11188287 (opens in a new tab)DOI10.1186/s13104-024-06820-w (opens in a new tab)PepBankPUB-38902794
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Objective and results descriptionThe study objective was to investigate the potential of quantitative measures of pulmonary inflammation by [18 F]Fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) as a surrogate marker of inflammation in COPD. Patients treated with anti-inflammatory Liraglutide were compared to placebo and correlated with inflammatory markers. 27 COPD-patients (14 receiving Liraglutide treatment and 13 receiving placebo) underwent 4D-respiratory-gated FDG-PET/CT before and after treatment. Two raters independently segmented the lungs from CT images and measured activity in whole lung, mean standard uptake values (SUVmean) corrected for lean-body-mass in the phase-matched PET images of the whole segmented lung volume, and total lesion glycolysis (TLG; SUVmean multiplied by volume). Inter-rater reliability was analyzed with Bland-Altman analysis and correlation plots. We found no differences in metabolic activity in the lungs between the two groups as a surrogate of pulmonary inflammation, and no changes in inflammation markers. The purpose of the research and brief summary of main findings. The degree of and changes in pulmonary inflammation in chronic obstructive pulmonary disease (COPD) may be difficult to ascertain. Measuring metabolic activity as a surrogate marker of inflammation by FDG-PET/CT may be useful, but data on its use in COPD including reproducibility is still limited, especially with respiration-gated technique, which should improve quantification in the lungs. We assessed several quantitative measures of metabolic activity and correlated them with inflammation markers, and we assessed reproducibility of the methods. We found no differences in metabolic activity between the two groups (before and after 40 weeks treatment with Liraglutide vs. placebo). Bland-Altman analysis showed good agreement between the two raters.Trial registrationThe study was conducted between February 2018 and March 2020 at the Department of Pulmonary Diseases at Hospital South West Jutland and Lillebaelt Hospital, Denmark, and registered from March 2018 at clinicaltrials.gov with trial registration number NCT03466021.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with COPD, liraglutide for 40 weeks did not change lung metabolic activity on FDG-PET/CT, a surrogate of inflammation, versus placebo.

    In plain wordsIn adults with COPD, liraglutide did not change lung inflammation on PET scans compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeLung metabolic activity on FDG-PET/CT
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Respiratory
    Studied dose
    Dose not stated · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    We found no differences in metabolic activity in the lungs between the two groups as a surrogate of pulmonary inflammation, and no changes in inflammation markers.
    2 context sentences
    Summary · context
    We found no differences in metabolic activity between the two groups (before and after 40 weeks treatment with Liraglutide vs. placebo).
    Summary · context
    27 COPD-patients (14 receiving Liraglutide treatment and 13 receiving placebo) underwent 4D-respiratory-gated FDG-PET/CT before and after treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with COPD, liraglutide did not change inflammation markers versus placebo.

    In plain wordsIn adults with COPD, liraglutide did not change inflammation markers compared with placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeInflammation markers
    Study

    n = 27

    Comparator
    Placebo
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 40 weeksAs given in this study (human).

    Source sentences

    Summary
    no changes in inflammation markers.
    1 context sentence
    Summary · context
    27 COPD-patients (14 receiving Liraglutide treatment and 13 receiving placebo) underwent 4D-respiratory-gated FDG-PET/CT before and after treatment.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 03HumanNot a test of Liraglutide aloneRandomized controlled trialOther

    In COPD patients, Bland-Altman analysis showed good agreement between two raters for FDG-PET/CT lung segmentation measures.

    In plain wordsIn COPD patients, two raters measuring the lung scans agreed well, which shows the method is reproducible.

    Peptide
    Liraglutide
    Outcome
    Not applicableInter-rater agreement of lung segmentation
    Study

    n: not reported in source

    Outcome group
    Inflammation markers · Respiratory

    Source sentences

    Summary
    Bland-Altman analysis showed good agreement between the two raters.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT03466021

Effects of Liraglutide in Chronic Obstructive Pulmonary Disease

Claus Bogh Juhln = 401 Jan 2018 to 31 May 2020

Pulmonary Disease, Chronic Obstructive

Trial pageClinicalTrials.govUpdated 16 Mar 2021

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.